 PHILADELPHIA, June 22, 2021 GLOBE NEWSWIRE -- Century Therapeutics NASDAQ: IPSC, an innovative biotechnology company developing induced pluripotent stem cell iPSC-derived cell therapies in immuno-oncology, today announced the closing of its initial public offering of 12,132,500 shares of its common stock at a public offering price of 20.00 per share, which includes the full exercise by the underwriters of their option to purchase 1,582,500 additional shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Century, were approximately 242.7 million. All the shares of common stock were offered by Century. 